ANSWER: B

Rationale:

The correct answer is B. The standard protocol for sublingual nitroglycerin (SL-NTG) in acute angina is one tablet (or spray, 0.4 mg) under the tongue at symptom onset; the patient should sit or lie down. If no relief after 5 minutes, a second tablet may be taken; if still no relief after another 5 minutes, a third tablet. If chest pain is not relieved after three doses over approximately 15 minutes, emergency services must be activated immediately — persistent pain unresponsive to three doses of nitroglycerin must be treated as a possible acute coronary syndrome. SL-NTG has an onset of 1–3 minutes and peak effect at approximately 5 minutes, which is why the 5-minute repeat interval is used.

• Option A: Option A is incorrect: repeating every 10 minutes for up to five doses and waiting up to one hour before calling EMS is dangerously prolonged in the setting of a possible evolving myocardial infarction.
• Option C: Option C is incorrect: SL-NTG must not be swallowed — oral nitroglycerin undergoes approximately 99% first-pass hepatic extraction and has virtually no systemic bioavailability; the tablet must dissolve under the tongue. The 30-minute repeat interval and 90-minute delay before EMS activation are also dangerous.
• Option D: Option D is incorrect: a 20-minute interval before the second dose ignores the drug's 1–3 minute onset and 5-minute peak — waiting 20 minutes is clinically inappropriate and potentially harmful in ACS.
• Option E: Option E is incorrect: there is no clinical indication to take two tablets simultaneously; doubling the initial dose increases hypotension risk without improving efficacy, and the dosing interval described delays appropriate emergency evaluation.

ANSWER: D

Rationale:

The correct answer is D. The nitrate-free interval (NFI) is the only strategy that reliably prevents and reverses all three mechanisms of nitrate tolerance. During the NFI: oxidatively inactivated mitochondrial aldehyde dehydrogenase 2 (ALDH2) is regenerated, restoring the enzymatic capacity to bioactivate nitroglycerin; neurohormonal pseudotolerance — activation of the renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system (SNS) from nitrate-induced hypotension — resolves as blood pressure normalizes; and vascular superoxide levels decrease, restoring nitric oxide (NO) bioavailability and soluble guanylyl cyclase (sGC) responsiveness. An NFI of at least 8–12 hours daily is required for all long-acting nitrate formulations.

• Option A: Option A is incorrect: dose escalation does not restore ALDH2 function — ALDH2 inactivation is oxidative and irreversible within the tolerance time frame, not a substrate saturation phenomenon that responds to higher drug concentrations.
• Option B: Option B is incorrect: adding a PDE5 inhibitor is absolutely contraindicated with nitrates due to dangerous cGMP potentiation causing severe hypotension; it cannot be used clinically as a tolerance management strategy.
• Option C: Option C is incorrect: rotating between different nitrate formulations does not prevent tolerance if each formulation is used continuously; tolerance develops from continuous NO production by any nitrate, not from accumulation specific to one formulation.
• Option E: Option E is incorrect: ACE inhibitors partially reverse pseudotolerance by attenuating RAAS-mediated vasoconstriction and sodium retention, but they do not prevent ALDH2 inactivation — the primary tolerance mechanism — and are therefore not fully effective as a sole anti-tolerance strategy.

ANSWER: A

Rationale:

The correct answer is A. In hypertrophic obstructive cardiomyopathy (HOCM), dynamic obstruction of the left ventricular outflow tract (LVOT) is caused by systolic anterior motion of the anterior mitral leaflet toward the hypertrophied interventricular septum. The severity of LVOT obstruction is directly dependent on left ventricular volume: a smaller LV cavity during systole brings the anterior mitral leaflet closer to the hypertrophied septum, worsening obstruction and reducing forward cardiac output. Any intervention that reduces LV filling — including nitroglycerin-induced venodilation with reduced venous return, dehydration, the Valsalva maneuver, or standing — decreases LV volume and can precipitate severe LVOT obstruction, syncope, or hemodynamic collapse. Organic nitrates are therefore absolutely contraindicated. The correct management of angina in HOCM uses agents that increase LV volume or reduce the LVOT gradient: beta-blockers reduce heart rate and contractility; verapamil improves diastolic filling and reduces the gradient.

• Option B: Option B is incorrect: reflex tachycardia from nitrates does worsen HOCM (shortened diastolic filling reduces LV volume), but it is not the primary mechanism of the absolute contraindication — the preload reduction and consequent LV volume reduction is.
• Option C: Option C is incorrect: cGMP does not sensitize cardiomyocytes to calcium; cGMP mediates vascular smooth muscle relaxation and does not produce direct myocardial calcium channel effects.
• Option D: Option D is incorrect: nitrates at standard doses produce predominant venodilation (preload reduction), not arteriolar dilation (afterload reduction); afterload reduction would theoretically benefit LVOT obstruction by reducing the gradient, not worsen it.
• Option E: Option E is incorrect: coronary steal in the hypertrophied septum is not an established mechanism of nitrate contraindication in HOCM.

ANSWER: C

Rationale:

The correct answer is C. Nitric oxide (NO) released from organic nitrates diffuses freely into vascular smooth muscle cells and binds to the heme iron of soluble guanylyl cyclase (sGC), activating this enzyme. Activated sGC converts GTP to cyclic GMP (cGMP). Elevated cGMP activates protein kinase G (PKG), which phosphorylates myosin light chain kinase (MLCK), reducing its catalytic activity. Since MLCK is required to phosphorylate myosin light chains — the obligatory step for actin-myosin cross-bridge cycling and smooth muscle contraction — reduced MLCK activity decreases myosin light chain phosphorylation and produces smooth muscle relaxation and vasodilation. This NO-sGC-cGMP-PKG-MLCK cascade is the core molecular mechanism of organic nitrate action.

• Option A: Option A is incorrect: the cAMP-PKA pathway is the mechanism of beta-2 adrenoceptor agonists and prostacyclin in smooth muscle relaxation — NO acts via guanylyl cyclase and cGMP, not adenylyl cyclase and cAMP.
• Option B: Option B is incorrect: while PKG activation downstream of cGMP does contribute to BKCa channel opening, NO does not directly open BKCa channels independently of the sGC-cGMP-PKG second messenger cascade; the description omits the essential intermediate steps.
• Option D: Option D is incorrect: NO does not directly inhibit L-type calcium channels at the channel protein; L-type channel closure occurs as a downstream consequence of PKG activation, not as a direct NO effect on the channel.
• Option E: Option E is incorrect: the PLC-IP3 pathway describes a contractile signaling cascade, not a relaxation mechanism; NO acts in the opposite direction from this pathway.

ANSWER: E

Rationale:

The correct answer is E. ST elevation in lead V4R (right-sided precordial lead) is the diagnostic finding of right ventricular (RV) infarction, complicating approximately 30–50% of inferior wall STEMIs. The infarcted RV cannot generate normal contractile force and becomes critically dependent on venous return and filling pressure (preload) to maintain output across the pulmonary vasculature. Nitroglycerin's primary hemodynamic action is venodilation with reduction in venous return — removing exactly the preload reserve the failing RV depends upon. The result is collapse of RV output, loss of LV filling, and precipitous systemic hypotension. The correct management is volume loading with isotonic saline (0.9% NaCl) to restore right ventricular preload and output — the opposite of vasodilation. Nitroglycerin must be withheld entirely.

• Option A: Option A is incorrect: while SBP below 90 mmHg is a general nitrate caution, the specific absolute contraindication is RV infarction physiology — preload dependence — not the blood pressure threshold alone. Volume loading, not dopamine, is the correct first-line treatment for RV infarction hypotension.
• Option B: Option B is incorrect: IV-NTG is recommended (Class I) for persistent ischemic symptoms and pulmonary congestion in most STEMI presentations; the contraindication is specific to RV infarction. Primary PCI addresses reperfusion but does not substitute for the hemodynamic management decision.
• Option C: Option C is incorrect: PDE5 inhibitor use cannot be assumed from demographics or hemodynamic findings; it requires direct patient questioning. Calcium gluconate is not the antidote for the nitrate-PDE5 interaction.
• Option D: Option D is incorrect: nitroglycerin does not have vagolytic or direct AV nodal effects; AV block in inferior STEMI is caused by ischemia of the AV nodal artery, not by nitrate administration.

ANSWER: B

Rationale:

The correct answer is B. Nitrate-induced headache is the most common adverse effect of organic nitrates, affecting approximately 30–60% of patients at initiation. The mechanism is nitric oxide (NO)-mediated vasodilation of cerebrovascular vessels, producing a throbbing frontal headache that begins within minutes of drug administration. A critically important teaching point is that cephalic tolerance — tolerance of the headache response — develops faster than hemodynamic tolerance — tolerance of the vasodilatory anti-ischemic effect. Within 1–2 weeks of regular dosing, the headache diminishes substantially or resolves in most patients while meaningful anti-ischemic benefit is preserved. Management is acetaminophen during this initial period, and the patient must be explicitly counseled that the headache is expected, not dangerous, and does not indicate loss of drug efficacy. Abrupt discontinuation of the nitrate due to headache is one of the most common causes of subtherapeutic nitrate use.

• Option A: Option A is incorrect: nitrate-induced headache reflects cerebrovascular vasodilation, not systemic hypotension causing cerebral hypoperfusion; a patient with significant hypotension would present with dizziness, presyncope, or syncope, not isolated frontal headache.
• Option C: Option C is incorrect: cephalic tolerance and hemodynamic tolerance are distinct processes developing at different rates; headache onset does not indicate loss of anti-ischemic efficacy, and it is headache resolution — not onset — that reflects cephalic tolerance developing.
• Option D: Option D is incorrect: organic nitrates do not cause intracranial hypertension; the headache is vascular in mechanism and does not represent increased cerebrospinal fluid pressure or a neurosurgical emergency.
• Option E: Option E is incorrect: the headache is not caused by rebound hypertension during the NFI; it is caused by NO-mediated vasodilation immediately after dosing. Taking an additional bedtime dose would eliminate the nitrate-free interval and cause hemodynamic tolerance.

ANSWER: D

Rationale:

The correct answer is D. Isosorbide mononitrate (ISMN) is the pharmacologically active mononitrate form — already in its active state, it undergoes negligible first-pass hepatic metabolism and achieves approximately 100% oral bioavailability. Plasma concentrations after a given dose are therefore consistent and predictable between patients. Isosorbide dinitrate (ISDN), by contrast, undergoes approximately 75% first-pass hepatic extraction, leaving an oral bioavailability of only approximately 25%. Because first-pass extraction depends on hepatic blood flow and enzyme expression — both of which vary considerably between individuals — ISDN plasma concentrations after a fixed oral dose are highly variable and unpredictable. This pharmacokinetic superiority of ISMN (not potency or half-life differences) is the primary reason ISMN has supplanted ISDN for chronic outpatient stable angina management.

• Option A: Option A is incorrect: the bioavailability values are inverted — ISMN has ~100% and ISDN has ~25%; preferring ISDN for higher bioavailability is pharmacologically backwards.
• Option B: Option B is incorrect: ISMN has ~100% bioavailability, not 25%; ISDN has ~25%, not 100%; neither value is correct in this option.
• Option C: Option C is incorrect: only ISMN is a preformed active mononitrate that bypasses first-pass metabolism; ISDN is a dinitrate prodrug that undergoes extensive hepatic first-pass extraction to yield active mononitrate metabolites.
• Option E: Option E is incorrect: the stated bioavailability values (50% for ISMN and 75% for ISDN) are both incorrect; the difference between the two drugs is driven by first-pass hepatic extraction, not gastrointestinal absorption efficiency.

ANSWER: A

Rationale:

The correct answer is A. Tadalafil has a plasma half-life of approximately 17.5 hours — substantially longer than sildenafil (approximately 4 hours) and vardenafil (approximately 4–5 hours). Clinically significant plasma concentrations of tadalafil persist for up to 48 hours after ingestion, which is why the absolute contraindication to all nitrate formulations is set at 48 hours for tadalafil — compared with 24 hours for sildenafil and vardenafil. At 20 hours post-ingestion, tadalafil plasma concentrations remain substantial and the interaction risk is fully present. The pharmacodynamic mechanism is additive cyclic GMP accumulation: nitrates generate NO which increases cGMP production via soluble guanylyl cyclase (sGC); PDE5 inhibitors prevent cGMP degradation. The combination produces dramatically potentiated vasodilation causing severe, potentially fatal hypotension. Nitroglycerin must be withheld and ACS pain managed with intravenous morphine, supplemental oxygen, and IV fluids.

• Option B: Option B is incorrect: the 24-hour window applies to sildenafil and vardenafil, not to tadalafil; applying the shorter window to tadalafil is a dangerous error that ignores its prolonged pharmacokinetic profile.
• Option C: Option C is incorrect: the PDE5 inhibitor-nitrate interaction is an absolute contraindication; no half-dose protocol renders it safe within the contraindication window.
• Option D: Option D is incorrect: the absolute contraindication applies to all nitrate formulations regardless of route — sublingual, oral, transdermal, and intravenous.
• Option E: Option E is incorrect: the interaction is an absolute, not relative, contraindication; no blood pressure threshold makes nitrate administration safe within the 48-hour tadalafil window.

ANSWER: C

Rationale:

The correct answer is C. Long-acting organic nitrates — including isosorbide mononitrate, isosorbide dinitrate, and transdermal nitroglycerin — are effective anti-anginal and anti-ischemic agents. They reduce anginal episode frequency, increase exercise duration before the ischemic threshold, and improve quality of life. However, no randomized controlled trial has demonstrated that long-acting nitrates reduce mortality, myocardial infarction, or other hard cardiovascular endpoints in stable coronary artery disease. Their mechanism — venodilation reducing preload and wall stress, epicardial coronary vasodilation, and modest platelet inhibition — does not translate to the plaque-stabilizing, anti-thrombotic, or mortality-reducing benefits of beta-blockers (post-MI), ACE inhibitors, statins, or antiplatelet agents. Isosorbide mononitrate should always be co-prescribed with evidence-based disease-modifying therapies, which carry the mortality and MI prevention benefit the patient is asking about.

• Option A: Option A is incorrect: while nitrates modestly inhibit platelet aggregation via cGMP, this effect is not clinically meaningful for MI prevention and has not been demonstrated to reduce events when added to aspirin in stable CAD.
• Option B: Option B is incorrect: no outcome trial has demonstrated cardiovascular mortality reduction with long-acting nitrates in stable CAD; describing this as evidence-based is inaccurate.
• Option D: Option D is incorrect: while nitrates reduce vasospastic angina episodes, no trial has demonstrated reduction in sudden cardiac death from coronary vasospasm-triggered arrhythmia; furthermore, vasospasm is not the most common trigger of fatal arrhythmias in stable CAD.
• Option E: Option E is incorrect: no subset of stable CAD patients — including those with prior MI — has been shown to derive mortality or MI reduction benefit from long-acting nitrates in randomized trial evidence.

ANSWER: E

Rationale:

The correct answer is E. Transdermal nitroglycerin patches contain a metallic foil component in their backing material. When a direct current electrical shock is delivered during cardioversion or defibrillation, this foil can conduct and concentrate the electrical energy, causing arcing between the patch and the skin. The result is a full-thickness burn at the patch site. This is a well-recognized procedural safety hazard that applies to all transdermal drug delivery patches with metallic foil backings — not only nitroglycerin patches. Mandatory pre-cardioversion preparation includes removing all transdermal patches from the patient's skin, inspecting for any residual foil or adhesive, and ensuring defibrillation or cardioversion pads are not placed over prior patch sites. This requirement applies equally to emergent defibrillation in cardiac arrest.

• Option A: Option A is incorrect: there is no clinical indication to double the nitrate dose before cardioversion, and doing so would keep the metallic foil present and increase hypotension risk post-procedure.
• Option B: Option B is incorrect: covering the patch with a non-conductive gel does not eliminate the risk of electrical arcing through the metallic foil — the patch must be physically removed.
• Option C: Option C is incorrect: moving the patch to a different body area does not eliminate the burn risk from shock delivery; any metallic foil in contact with skin during electrical cardioversion poses a burn hazard regardless of location.
• Option D: Option D is incorrect: leaving the patch in place even away from electrode sites remains hazardous during transthoracic current delivery; the patch must be removed, not repositioned.

ANSWER: B

Rationale:

The correct answer is B. The primary molecular mechanism of organic nitrate tolerance is oxidative inactivation of mitochondrial aldehyde dehydrogenase 2 (ALDH2). During nitroglycerin (GTN) bioactivation, ALDH2 catalyzes the denitration of GTN to generate inorganic nitrite and subsequently nitric oxide (NO). This reaction generates reactive oxygen species as byproducts — specifically superoxide and peroxynitrite — that oxidatively damage and irreversibly inactivate ALDH2 itself. The enzyme required to produce NO is progressively destroyed by the process of producing it, reducing NO generation and the vasodilatory response with continued nitrate exposure. ALDH2 inactivation is supported by the most direct experimental evidence, including studies demonstrating marked falls in ALDH2 activity during GTN infusion and restoration during the nitrate-free interval (NFI).

• Option A: Option A is incorrect: PDE5 upregulation is a proposed secondary adaptation in chronic NO exposure but is not the primary established mechanism of acute nitrate tolerance; ALDH2 inactivation precedes and dominates.
• Option C: Option C is incorrect: sGC downregulation has been proposed as a contributing molecular adaptation but is not the primary established mechanism; experimental evidence places ALDH2 inactivation as the primary driver.
• Option D: Option D is incorrect: the oxidative inactivation of ALDH2 is covalent and irreversible within the tolerance time frame — not a reversible competitive inhibition by metabolic byproducts. Nitroglycerin metabolites do not competitively occupy the ALDH2 active site.
• Option E: Option E is incorrect: neurohormonal RAAS and SNS activation describes pseudotolerance — a genuine but secondary component of nitrate tolerance. While clinically important, it does not fully account for tolerance observed in experimental systems where neurohormonal responses are controlled, confirming that ALDH2 inactivation is the primary molecular mechanism.